Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;40(8):1721-1726.
doi: 10.1007/s10096-021-04202-9. Epub 2021 Mar 20.

Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19

William Stokes  1   2   3 , Byron M Berenger  4   5 , Danielle Portnoy  6 , Brittney Scott  6 , Jonas Szelewicki  6 , Takshveer Singh  7 , Allison A Venner  4   5 , LeeAnn Turnbull  4 , Kanti Pabbaraju  4 , Sandy Shokoples  4 , Anita A Wong  4 , Kara Gill  4 , Tracy Guttridge  4 , Dustin Proctor  4   5 , Jia Hu  8   9 , Graham Tipples  4   10   11
Affiliations

Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19

William Stokes et al. Eur J Clin Microbiol Infect Dis. 2021 Aug.

Abstract

SARS-CoV-2 antigen tests used at the point-of-care, such as the Abbott Panbio, have great potential to help combat the COVID-19 pandemic. The Panbio is Health Canada approved for the detection of SARS-CoV-2 in symptomatic individuals within the first 7 days of COVID-19 symptom onset(s). Symptomatic adults recently diagnosed with COVID-19 in the community were recruited into the study. Paired nasopharyngeal (NP), throat, and saliva swabs were collected, with one paired swab tested immediately with the Panbio, and the other transported in universal transport media and tested using real-time reverse-transcriptase polymerase chain reaction (RT-PCR). We also prospectively evaluated results from assessment centers within the community. For those individuals, an NP swab was collected for Panbio testing and paired with RT-PCR results from parallel NP or throat swabs. One hundred and forty-five individuals were included in the study. Collection of throat and saliva was stopped early due to poorer performance (throat sensitivity 57.7%, n=61, and saliva sensitivity 2.6%, n=41). NP swab sensitivity was 87.7% [n=145, 95% confidence interval (CI) 81.0-92.7%]. There were 1641 symptomatic individuals tested by Panbio in assessment centers with 268/1641 (16.3%) positive for SARS-CoV-2. There were 37 false negatives and 2 false positives, corresponding to a sensitivity and specificity of 86.1% [95% CI 81.3-90.0%] and 99.9% [95% CI 99.5-100.0%], respectively. The Panbio test reliably detects most cases of SARS-CoV-2 from adults in the community setting presenting within 7 days of symptom onset using nasopharyngeal swabs. Throat and saliva swabs are not reliable specimens for the Panbio.

Keywords: Antigen; COVID-19; Panbio; Point of care testing (POCT); Rapid diagnostics; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Sensitivity between Panbio and RT-PCR in symptomatic individuals known to have COVID-19 [n=145 for nasopharyngeal (NP) specimens, 61 for throat (Th), 41 for saliva (Sa)] with 95% confidence intervals
See this image and copyright information in PMC

References

    1. Abbott. Panbio: COVID-19 Ag rapid test device. 2020. [Accessed Dec 25, 2020]. Available at: https://www.who.int/diagnostics_laboratory/eual/eul_0564_032_00_panbi_co....
    1. Fenollar F, Bouam A, Ballouche M, et al. Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19. J Clin Microbiol. 2020;59:e02589–e02520. - PMC - PubMed
    1. Gremmels, et al. Real-life validation of the Panbio COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. MedRxiv. 2020. [Accessed Dec 25, 2020]. Available from: https://www.medrxiv.org/content/10.1101/2020.10.16.20214189v1. - DOI - PMC - PubMed
    1. Linares M, Pérez-Tanoira R, Carrero A, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. J Clin Virol. 2020;133:104659. doi: 10.1016/j.jcv.2020.104659. - DOI - PMC - PubMed
    1. Albert E, Torres I, Bueno F et al (2020) Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centers. Clin Microbiol Infect. 10.1016/j.cmi.2020.11.004 - PMC - PubMed

Publication types